The antimicrobial susceptibility testing market is projected to reach USD 4.7 Billion in 2027 from 3.6 Billion in 2022 at a CAGR of 5.5% during the forecast period. The high prevalence of infectious diseases, rising government funding and initiatives for antimicrobial susceptibility testing programs, technological developments for the creation of new AST methods, and the emergence of multidrug resistance in microorganisms are the main factors driving the antimicrobial susceptibility testing market. However, strict government controls are anticipated to limit this market's expansion to some degree. Players in the antimicrobial susceptibility testing market may anticipate having tremendous growth potential as a result of emerging markets and ongoing R&D to provide quick antimicrobial susceptibility testing.
The Antimicrobial susceptibility testing market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2021, the key players operating in the Antimicrobial susceptibility testing market are bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), HiMedia Laboratories (India), Liofilchem S.R.L Diagnostics (Italy), Alifax S.r.l. (Italy), Creative Diagnostics (US), Synbiosis (UK), Bioanalyse (Turkey), ZHUHAI DL BIOTECH Co., Ltd. (China), ELITechGroup (France), Mast Group Ltd. (UK), CONDALAB (Spain), Genefluidics, Inc. (US), Biotron Ltd. (Australia), InvivoGen (US), MP Biomedicals (US), QuantaMatrix Inc. (South Korea), and PML Microbiologicals Inc. (US), among others.
To know about the assumptions considered for the study download the pdf brochure
To further increase their market share in the Antimicrobial susceptibility testing market, these competitors have utilized a variety of strategies, including acquisitions, agreements, partnerships, and product releases. In 2022, a higher share of the Antimicrobial susceptibility testing market was held by bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), and Bio-Rad Laboratories, Inc. (US)
bioMérieux SA (bioMérieux) is a provider of diagnostic solutions for medical and industrial applications. These products are used to diagnose cardiovascular diseases, targeted cancers, and infectious diseases. The company also provides various in vitro diagnostic solutions to hospitals.
bioMérieux offers sterility and quality testing solutions for the cosmetics, pharmaceutical, and food sectors. The company operates through five segments, namely, Microbiology, Molecular Biology, Immunoassays, Industrial Applications, and Other Lines. bioMérieux operates in the AST market through the Microbiology segment.
The company operates in more than 160 countries across North America, Europe, Oceania, Africa, and the Asia Pacific. It has 18 production sites and 18 R&D centers located across the globe, including the US, Brazil, China, Australia, Canada, France, and Spain. The company has 43 subsidiaries, including bioMérieux Singapore PTE LTD., bioMérieux Korea Co., Ltd. (South Korea), bioMérieux Suisse S.A. (Switzerland), bioMérieux Italy, bioMérieux Austria GmbH, bioMérieux Denmark, bioMérieux Germany, bioMérieux France, bioMérieux UK Limited, and bioMérieux Inc. (US).
Thermo Fisher Scientific
Thermo Fisher Scientific is engaged in the development, manufacturing, and marketing of analytical instruments, reagents & consumables, equipment, and software products. The company operates its businesses through four segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services. The microbiology business under the company’s Specialty Diagnostics segment offers dehydrated and prepared culture media, collection and transport systems, microbiology instrumentation, and consumables to detect pathogens in blood, diagnostic, and rapid direct specimen tests, quality-control products, and associated products for microbiology laboratories.
Thermo Fisher Scientific has a strong geographic presence in more than 150 countries across North America, the Asia Pacific, Europe, and Latin America. Some of its major subsidiaries are Thermo Fisher Scientific Peru S.A., Laboratory Management Systems, Inc. (US), Open BioSystems, Inc. (US), Thermo Electron Australia Pty Limited, Lomb Scientific Pty Limited (Australia), Thermo Scientific Korea Ltd. (South Korea), Fisher Clinical Services Limited Liability Company (Russia), Fisher Clinical Services Japan K.K., and Thermo Fisher Scientific C.V. (Netherlands).
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is engaged in the development, manufacture, and marketing of medical devices, instrument systems, and reagents. BD operates through three business segments—BD Medical, BD Life Sciences, and BD Interventional. The Life Sciences division is further divided into Diagnostic Systems, Preanalytical Systems, and Biosciences sub-divisions. The company offers antimicrobial susceptibility testing products under the Diagnostic Systems segment of its Life Sciences division. The company’s end users mainly include healthcare institutions, clinical laboratories, life science researchers, and the pharmaceutical industry, among others.
BD has a presence in more than 190 countries across North America, Europe, EMA (which includes the Commonwealth of the Independent States, the Middle East, and Africa), the Asia Pacific, and Latin America. Some of its major subsidiaries are CareFusion Corporation (US), Becton Dickinson Infusion Therapy Systems Inc. (US), BD Rapid Diagnostic (Suzhou) Co., Ltd. (China), BD Holding S. de R.L. de C.V. (Mexico), Becton Dickinson Canada Inc., Becton Dickinson India Private Limited, Becton Dickinson Korea Holding, Inc. (US), Becton Dickinson Ltd. (New Zealand), Becton, Dickinson A.G. (Switzerland), Becton Dickinson Asia Limited (Hong Kong), Becton Dickinson France S.A.S., Becton Dickinson (Mauritius) Limited, and Nippon Becton Dickinson Company, Ltd. (Japan).
Danaher Corporation is engaged in designing, manufacturing, and marketing medical, professional, industrial, and commercial products & services. The company operates through four business segments—Environmental & Applied Solutions, Dental, Life Sciences, and Diagnostics. The Diagnostics segment offers a wide range of products, such as analytical instruments, consumables, reagents, software, and services. The Diagnostics segment is further categorized into clinical lab diagnostics, molecular diagnostics, critical care diagnostics, and anatomical pathology diagnostics. The Diagnostics segment offers products under the Danaher Corporation, Cepheid, Iris, Leica Biosystems, Hemocue, Mammatome, Radiometer, and Surgipath brands. The company offers AST products through its Diagnostics segment.
Danaher has a significant presence in the US, China, Denmark, Germany, Singapore, the UK, and Switzerland. Some of the important subsidiaries of the company are Danaher Canadian Holdings LP (Ontario), Danaher Hong Kong Ltd. (Hong Kong), Dr. Lange Nederland B.V. (Netherlands), Fluke China Limited (China), Leica Microsistemas SA (Spain), LEM Instruments (UK), Namco Controls Corporation (US), and Sendx Medical Inc. (US).
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (Bio-Rad) is engaged in developing, manufacturing, and supplying life sciences and clinical diagnostic tools and services. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Sciences segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company operates in the market through the Clinical Diagnostics segment.
The company has direct distribution channels in over 35 countries outside the US. It has operations across the US, Canada, Latin America, Europe, and the Pacific Rim. Some of its key subsidiaries are Bio-Rad Laboratories Pty. Limited (Australia), Bio-Rad Laboratorios Brasil Ltda. (Brazil), Bio-Rad Laboratories N.V. (Belgium), Bio-Rad Laboratories G.m.b.H. (Germany), Bio-Rad Haifa Ltd. (Israel), and Bio-Rad Laboratories K.K. (Japan).
Antimicrobial Susceptibility Testing Market by Product (Manual, Automated), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion,Agar Diffusion,Genotyping), End-User - Global Forecasts to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE